Health
Lilly to Spend $27 Billion to Bolster US Drug Manufacturing
Officials described Lilly’s investments over the past five years as the most ambitious manufacturing expansion in the company’s history.
Photographer: Daniel Acker/BloombergThis article is for subscribers only.
Eli Lilly & Co. will spend at least $27 billion to build four US manufacturing plants, the latest company to brace for the potential impact of President Donald Trump’s tariffs.
Three facilities will make active ingredients for Lilly’s drugs, the company said Wednesday, bringing critical processes that are typically done overseas to American shores. Another plant will expand manufacturing capacity for Lilly’s pipeline of injectable drugs.